# US 2024/0002812 A1 · Methods of preparing gene therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002812 A1
- Document ID: US20240002812A1
- Status: Published application
- Kind: A1
- Application number: 18/319,350
- Filed: 2023-05-17
- Published: 2024-01-04
- Earliest claimed: 2022-05-17
- Assignees: BridgeBio Services Inc.
- Applicants: BridgeBio Services Inc.
- Inventors: Ashton LAVOIE; Jeffrey Zugates
- Web page: https://patentgrep.com/patent/US20240002812A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- G01N 30/02: Column chromatography
- G01N 30/06: Preparation
- G01N 30/88: Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- C12N 2750/14151: Methods of production or purification of viral material
- G01N 2030/027: {Liquid chromatography}
- G01N 2030/8818: {involving amino acids}
- G01N 2030/8827: {involving nucleic acids}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The disclosure provides methods for purifying gene therapy compositions using anion exchange chromatography.

## Claims

### Claim 1

A method, comprising:
a) providing a mixture comprising a plurality of recombinant adeno-associated (rAAV) vector particles and one or more impurities, wherein rAAV vector particles of said plurality of rAAV vector particles each include a therapeutic nucleic acid molecule, and wherein said one or more impurities comprise rAAV vector particle aggregates, rAAV vector particles that do not include said therapeutic nucleic acid molecule, and aggregates of rAAV vector particles and rAAV vector particles that do not include said therapeutic nucleic acid molecule;
b) contacting an anion exchange column with said mixture; and
c) contacting said anion exchange column with a first elution buffer and a second elution buffer to provide an eluate, wherein said eluate comprises rAAV vector particles of said plurality of rAAV vector particles,
wherein said first elution buffer comprises magnesium sulfate; and
wherein said second elution buffer comprises magnesium sulfate and magnesium chloride.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first elution buffer comprises between about 0 millimolar (mM) to about 10 mM magnesium sulfate.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein said second elution buffer comprises between about 10 millimolar (mM) to about 50 mM magnesium sulfate.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein said second elution buffer comprises between about 10 millimolar (mM) to about 50 mM magnesium chloride.

### Claim 7

(canceled)

### Claim 8

A method, comprising:
a) providing a mixture comprising a plurality of recombinant adeno-associated (rAAV) vector particles and one or more impurities, wherein rAAV vector particles of said plurality of rAAV vector particles each include a therapeutic nucleic acid molecule, and wherein said one or more impurities comprise rAAV vector particle aggregates, rAAV vector particles that do not include said therapeutic nucleic acid molecule, and aggregates of rAAV vector particles and rAAV vector particles that do not include said therapeutic nucleic acid molecule;
b) contacting an anion exchange column with said mixture; and
c) contacting said anion exchange column with a first elution buffer and a second elution buffer to provide an eluate, wherein said eluate comprises rAAV vector particles of said plurality of rAAV vector particles,
wherein said first elution buffer comprises a sulfate salt; and
wherein said second elution buffer comprises a sulfate salt and a chloride salt.

### Claim 9

A method, comprising:
a) providing a mixture comprising a plurality of recombinant adeno-associated (rAAV) vector particles and one or more impurities, wherein rAAV vector particles of said plurality of rAAV vector particles each include a therapeutic nucleic acid molecule, and wherein said one or more impurities comprise rAAV vector particle aggregates, rAAV vector particles that do not include said therapeutic nucleic acid molecule, and aggregates of rAAV vector particles and rAAV vector particles that do not include said therapeutic nucleic acid molecule;
b) contacting an anion exchange column with said mixture; and
c) contacting said anion exchange column with a first elution buffer and a second elution buffer to provide an eluate, wherein said eluate comprises rAAV vector particles of said plurality of rAAV vector particles,
wherein said first elution buffer comprises a first salt; and
wherein said second elution buffer comprises a second salt and a third salt, wherein the total salt concentration of said second elution buffer is between about 40-250 millimolar (mM).

### Claim 10

(canceled)

### Claim 11 (depends on 9)

The method of claim 9, wherein the first elution buffer comprises between about 0 millimolar (mM) to about 10 mM magnesium sulfate.

### Claim at position 12

-13. (canceled)

### Claim 14 (depends on 9)

The method of claim 9, wherein said second elution buffer comprises between about 10 millimolar (mM) to about 50 mM magnesium sulfate.

### Claim at position 14

-16. (canceled)

### Claim 17 (depends on 9)

The method of claim 9, wherein said second elution buffer comprises between about 10 millimolar (mM) to about 50 mM magnesium chloride.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein said first elution buffer and/or said second elution buffer further comprises bis-tris propane.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein said first elution buffer and/or said second elution buffer further comprises a poloxamer.

### Claim at position 20

-23. (canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein said first elution buffer and/or said second elution buffer further comprises sucrose.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The method of claim 1, wherein said first elution buffer and/or said second elution buffer have a pH of about 9.0.

### Claim 27 (depends on 1)

The method of claim 1, wherein c) comprises initially contacting said anion exchange column with an eluant comprising 100% of said first elution buffer and 0% of said second elution buffer and then linearly decreasing the amount of said first elution buffer in said eluant to 0% and linearly increasing the amount of said second elution buffer in said eluant to 100%.

### Claim at position 25

-33. (canceled)

### Claim 34 (depends on 1)

The method of claim 1, wherein said anion exchange column comprises a strong anion exchange resin.

### Claim at position 27

-36. (canceled)

### Claim 37 (depends on 1)

The method of claim 1, wherein said anion exchange column is functionalized with quaternary amines.

### Claim 38

(canceled)

### Claim 39 (depends on 1)

The method of claim 1, further comprising, prior to a), (i) providing a solution comprising cells and said plurality of rAAV vector particles; (ii) lysing said cells of said solution to produce a lysate; (iii) filtering said lysate to produce a clarified lysate; and (iv) subjecting said clarified lysate to an affinity chromatography step to provide said mixture.

### Claim at position 31

-47. (canceled)

### Claim 48 (depends on 1)

The method of claim 1, wherein the rAAV of said rAAV vector particles are of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh32.33, AAVrh8, AAVrh10, AAVrh74, AAVhu.68, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, snake AAV, bearded dragon AAV, AAV2i8, AAV2g9, AAV-LK03, AAV7m8, AAV Anc80, or AAV PHP.B.

### Claim 49 (depends on 48)

The method of claim 48, wherein the rAAV of said rAAV vector particles are of serotype AAV5.

### Claim at position 34

-62. (canceled)
